semaglutide and naion use in patients with diabetes was associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) at 2, 3, 4 years. https://ja.ma/4iZkMeV Semaglutide and Nonarteritic Anterior Ischemic

In two analyses, Noom members were modeled to gain less than 2% of bodyweight up to 12 months after stopping medication with the strongest maintenance among those who continued practicing healthy habits Noom members regained 3x less of their lost weight at 12 months than published post-discontinuation benchmarks (21.2% vs

Most patients experience diarrhea during the first few weeks of treatment

Most patients starting with normal b12 levels and no significant risk factors do not require supplementation

As a unimolecular triple agonist, it targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors

Your individual response depends partly on genetics, body weight, and how long you've been on semaglutide